Reuters logo
BRIEF-‍Syndax announces dosing of first patient in trial of Entinostat for treatment of recurrent breast cancer
2017年10月5日 / 上午11点16分 / 19 天内

BRIEF-‍Syndax announces dosing of first patient in trial of Entinostat for treatment of recurrent breast cancer

Oct 5 (Reuters) - Syndax Pharmaceuticals Inc

* ‍Syndax announces dosing of first patient in pivotal trial of entinostat for treatment of advanced or recurrent breast cancer in Japan by partner kyowa hakko kirin​

* Syndax Pharmaceuticals Inc - ‍phase 2 trial is expected to enroll about 124 patients in Japan​

* Syndax Pharmaceuticals Inc - ‍enrollment of first patient in phase 2 trial of entinostat​ triggers $5 million milestone payment to Syndax Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below